Fate Therapeutics News

Canadian Investment Banking Group: Maintaining the Fate Therapeutics (FATE.US) rating, adjusted from buy to buy rating, and adjusted the target price from $11.00 to $9.00.

Zhitong FinanceMay 11 02:40

Fate Therapeutics Analyst Ratings

BenzingaMay 10 21:17

Piper Sandler Maintains Neutral on Fate Therapeutics, Lowers Price Target to $4

BenzingaMay 10 21:18

Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)

TipRanksMay 10 20:47

Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)

TipRanksMay 10 20:30

Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating

MT NewswiresMay 10 20:22

Fate Therapeutics: Strategic Shifts Prompt Hold Rating Amidst Awaited Clinical Results

TipRanksMay 10 18:29

Wedbush: Reiterates Fate Therapeutics (FATE.US) rating, adjusted from neutral to neutral, with a target price of $7.00.

Zhitong FinanceMay 6 20:31

Fate Therapeutics Analyst Ratings

BenzingaMay 6 20:22

Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target

BenzingaMay 6 20:23

Fate Therapeutics (FATE) Gets a Hold From Wedbush

TipRanksMay 6 19:55

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)

TipRanksApr 24 16:50

Fate Therapeutics Analyst Ratings

BenzingaApr 24 01:11

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)

TipRanksApr 11 18:20

Fate Therapeutics Analyst Ratings

BenzingaApr 11 18:08

Needham: Reiterates that Fate Therapeutics (FATE.US) holds the rating.

Zhitong FinanceApr 11 18:10

Fate Therapeutics Analyst Ratings

BenzingaMar 29 02:12

Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns

TipRanksMar 28 16:58

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)

TipRanksMar 26 09:10

Fate Therapeutics Analyst Ratings

BenzingaMar 19 18:52